JHU Ref #: C18159
Value Proposition
· Sustained release of small molecule that depletes white fat
· Local injectable administration with less intense dosing regimen
Unmet Need
· Excessive white fat accumulation, commonly associated with obesity, is a significant health concern that impacts metabolic, cardiovascular, and endocrine systems. White adipose tissue (WAT) serves as the body’s primary energy storage depot, but its excessive buildup disrupts normal metabolic functions, leading to a cascade of health issues. These include, but are not limited to, thyroid eye disease, diabetes, and endocrine disorders. Current treatment options often require frequent administration and can lead to widespread systemic side effects, limiting long-term use and patient adherence. Thus, there is a need for a sustained delivery system that provides similar efficacy with reduced side effects.
Technology Overview
· Johns Hopkins researchers have formulated Linsitinib nano- and microcrystals that inhibit adipogenesis. Linsitinib is a small molecule inhibitor of insulin growth factor type 1 receptor (IGF-1R), which transmits insulin’s actions to metabolic responses in systemic tissues, including adipose tissue. The molecule’s nanocrystal form allows for faster dissolution time and increased stability in culture. Furthermore, formulation as a nanocrystal reduces the toxicity of Linsitinib. Thus the researcher’s formulation allows for sustained release of the drug with improved efficacy and reduction of toxicity or dose-related side effects.
Stage of Development
· Preclinical animal testing with a plan to move into diabetic and other relevant animal models.
Data Availability
· N/A
Publication
· N/A
